Literature DB >> 19696060

Dysfunctional inflammasome in Schnitzler's syndrome.

Cinzia Pizzirani1, Simonetta Falzoni, Marcello Govoni, Renato La Corte, Simona Donadei, Francesco Di Virgilio, Francesco Trotta, Andrea Lo Monaco.   

Abstract

OBJECTIVE: IL-1beta plays a key role in the pathogenesis of Schnitzler's syndrome (SS). We have investigated inflammasome activity in peripheral blood mononuclear cells (PBMCs) from a patient affected by a variant type of SS.
METHODS: PBMCs were purified by Ficoll and examined for ability to secrete IL-1beta and -18, expression and function of the P2X(7) receptor and expression of apoptosis-associated speck-like protein containing a caspase recruitment domaine (ASC) and NOD-like receptor protein 3 (NLRP3) before and after the therapy with steroid. Furthermore, extracellular adenosine 5'-triphosphate (ATP) blood levels were determined by luciferase assay. Expression of inflammasome components was measured by real time PCR and western blotting.
RESULTS: PBMCs of patient with SS showed a high, spontaneous and lipopolysaccharide-stimulated, IL-1beta release but low response to stimulation with the P2X(7) agonist benzoyl ATP. P2X(7) expression was several fold increased, whereas ASC expression was dramatically decreased compared with PBMCs from healthy controls. NLRP3 expression was unchanged. Prednisone treatment induced remission of clinical symptoms and normalized IL-1beta secretion and P2X(7) and ASC expression.
CONCLUSION: These findings reveal the presence of an overall derangement of the inflammasome and IL-1beta processing and release in SS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696060     DOI: 10.1093/rheumatology/kep222

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  22 in total

Review 1.  Inflammasome-mediated autoinflammatory disorders.

Authors:  Shruti P Wilson; Suzanne L Cassel
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

Review 2.  The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.

Authors:  P Menu; J E Vince
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

3.  Schnitzler's syndrome associated with pancreatitis: a disease of IL-1 dysregulation.

Authors:  Cecilia A Larocca; John W McEvoy; Carla L Ellis; Jacqueline Junkins-Hopkins; Todd Kolb; Alan N Baer; Brian T Garibaldi
Journal:  Clin Rheumatol       Date:  2011-06-28       Impact factor: 2.980

Review 4.  Clinical immunology review series: An approach to the patient with a periodic fever syndrome.

Authors:  H J Lachmann
Journal:  Clin Exp Immunol       Date:  2011-07-07       Impact factor: 4.330

Review 5.  Autoinflammation: From monogenic syndromes to common skin diseases.

Authors:  Tien V Nguyen; Edward W Cowen; Kieron S Leslie
Journal:  J Am Acad Dermatol       Date:  2013-02-28       Impact factor: 11.527

6.  Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.

Authors:  Evangelia Zampeli; Leonidas Marinos; Stamatis J Karakatsanis
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

7.  Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Authors:  Dorota M Rowczenio; Shelly Pathak; Juan I Arostegui; Anna Mensa-Vilaro; Ebun Omoyinmi; Paul Brogan; Dan Lipsker; Thomas Scambler; Roger Owen; Hadija Trojer; Anna Baginska; Julian D Gillmore; Ashutosh D Wechalekar; Thirusha Lane; Rene Williams; Taryn Youngstein; Philip N Hawkins; Sinisa Savic; Helen J Lachmann
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

Review 8.  Inflammasomes and their activation.

Authors:  Sonal Khare; Nancy Luc; Andrea Dorfleutner; Christian Stehlik
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 9.  [Schnitzler syndrome].

Authors:  J Loock
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 10.  Targeting inflammasomes in rheumatic diseases.

Authors:  Alexander So; Annette Ives; Leo A B Joosten; Nathalie Busso
Journal:  Nat Rev Rheumatol       Date:  2013-05-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.